ArticleCell death & disease2019
The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression.
Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- A molecular landscape tracking the progression of non-muscle invasive bladder cancer.World journal of urology · 2026Review
- Shared molecular signatures between atrial fibrillation and chronic obstructive pulmonary disease: an integrated bioinformatic analysis with experimental validation.BMC medical genomics · 2026Article
- IFIT3 promotes lymph node metastasis by interacting with LASP1 to activate FAK-ERK signaling in esophageal squamous cell carcinoma.Cell death & disease · 2025Article
- Clinical Utility of IFIT Proteins in Human Malignancies.Biomedicines · 2025Review
- Article
- Review
- 2'-Hydroxyflavanone inhibits bladder cancer cell proliferation and angiogenesis via regulating miR-99a-5p/mTOR signaling.American journal of clinical and experimental urology · 2025Article
- IFIT3 accelerates the progression of head and neck squamous cell carcinoma by targeting PD-L1 to activate PI3K/AKT signaling pathway.World journal of surgical oncology · 2024Article
- The diagnostic/prognostic roles and biological function of the IFIT family members in acute myeloid leukemia.BMC medical genomics · 2023Article
- Review
- The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer.Clinical and translational medicine · 2022Article
- Article
- Integrative pan-cancer analysis and clinical characterization of the N7-methylguanosine (m7G) RNA modification regulators in human cancers.Frontiers in genetics · 2022Article
- Integrated analysis from multi-center studies identities m7G-derived modification pattern and risk stratification system in skin cutaneous melanoma.Frontiers in immunology · 2022Article
- Analysis of mFrontiers in immunology · 2022Article
- m7G-related gene NUDT4 as a novel biomarker promoting cancer cell proliferation in lung adenocarcinoma.Frontiers in oncology · 2022Article
- ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A.Cell death & disease · 2021Article
- Prognostic Value of Preoperative Albumin-to-Fibrinogen Ratio in Patients with Bladder Cancer.Journal of Cancer · 2021Article
- RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.OncoTargets and therapy · 2021Article
- A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of bladder cancer (BCa) depends on several key factors including anatomical site, tumor grade, and stage. In general, muscle-invasive bladder cancer (MIBC) is associated with higher incidence of distant metastasis compared with Non-muscle-invasive bladder cancer (NMIBC). Treatment outcome of the patients with metastatic BCa has been very poor with ~15% of overall survival rate. Thus, it is apparently important to understand the underlying biology for metastatic progression of BCa. Although epithelial-mesenchymal transition (EMT) has long been implicated in BCa metastasis and treatment resistance, the underlying mechanism is not fully understood. In this study, we have identified that the expression of interferon induced protein with tetratricopeptide repeats 5 (IFIT5) is positively correlated with pathological characteristics, and predicts a poor prognosis of BCa patients. Since the function of IFIT5 in BCa has not yet been characterized, we demonstrate that IFIT5 can induce EMT, promote cell migration and invasion, and increase the expression of ICAM1 in BCa via down-regulation of mature miR-99a. Moreover, ICAM1 is shown as a direct target of miR-99a. Overall, we conclude that IFIT5 is a new oncogene in BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.